Gilead Sciences saw its stock slip about 3% the day after earnings. The headline factor was not weak demand, but an earnings decline driven by heavy investment. The company reported a quarterly loss of about US$10.5b and basic earnings per share of a loss of US$8.44, while base product sales reached US$7.6b with solid contributions from HIV and oncology.

As a result, the stock, which had been roughly flat over the prior three months, is now trading lower. At the same time, the core drug portfolio is generating more revenue and the income statement is reflecting a substantial increase in acquired research and development spending.

Is Gilead Sciences now a genuine bargain after this loss driven quarter, or is the lower share price just a trap around an unprofitable trailing year and heavy R&D spend? Compare the current share price to the detailed cash flow based fair value work in the valuation analysis for Gilead Sciences

Q2 2026 Earnings Summary

• Total Revenue, Q2 2026 vs. Q2 2025: US$7,803m vs. US$7,082m (up about 10%)
• Net Income, Q2 2026 vs. Q2 2025: loss of US$10,496m vs. profit of US$1,960m (shifted from profit to a large loss)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$8.44 per share vs. earnings of US$1.57 per share (shifted from profit to a large loss per share)
• Base Product Sales, Q2 2026 vs. Q2 2025: US$7.6b vs. about US$6.9b (up about 10% for Gilead Sciences core drug portfolio)

Prefer clean charts over another wall of earnings tables and income statement line items? See Gilead Sciences’ full financial picture with an at-a-glance view of its valuation workup in the company report for Gilead Sciences.

Gilead Bull Case Hinges On HIV And Oncology Execution

The bullish story on Gilead Sciences is that a stronger HIV, oncology and liver portfolio can offset deal noise and support healthier earnings over time. Q2 results give that idea some concrete milestones. Base product sales grew 10% year on year to US$7.6b, with HIV up 12% to US$5.7b and PrEP crossing US$1b in quarterly sales. Yeztugo delivered US$232m, and rising persistency above 70% backs the claim that long acting HIV can be more than a niche.

Oncology is also moving in the direction the bull case wanted. Trodelvy reached US$457m, up double digits both year on year and sequentially after first line metastatic TNBC approvals. Liver disease now contributes US$877m, with Livdelzi more than doubling and Hepcludex launched in the US. The key trade off is that these wins are currently paired with very heavy acquired R&D, which keeps reported earnings in loss territory.

Compare that operational momentum in Gilead Sciences HIV and oncology franchises with how institutions are resetting their expectations. See the consensus price target analysis for Gilead Sciences to check where Wall Street thinks the stock should trade after this earnings reset.

Gilead Bear Case: Earnings Optics Still Look Heavy

The cautious view on Gilead Sciences says policy and competition will crimp HIV and oncology while heavy deal spending keeps margins under pressure. Q2 results only partly challenge that. HIV and base product sales moved higher and full year HIV growth guidance is now 9% to 10%, which pushes back on the idea that Medicare Part D changes are already biting hard. Yeztugo passing US$1b PrEP run rate with strong persistency also weakens the fear that long acting HIV would stall.

However, several bearish milestones are still intact. Cell therapy revenue fell 14% year on year, which lines up with concerns about competitive pressure in Kite. Veklury is now expected at about US$300m for 2026, so COVID tailwinds are effectively gone. Most importantly, around US$11.5b of acquired IPR&D this year keeps non GAAP EPS in loss territory, so margin pressure and complex earnings optics remain very real.

Review Gilead Sciences margin pressure, heavy acquired R&D, and debt load. Scan our completed risk analysis for Gilead Sciences which shows 2 important warning signs for potential hidden structural vulnerabilities.

Stay Ahead With Gilead Sciences And Simply Wall St

If Gilead Sciences heavy acquired R&D spend and mixed earnings picture has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value work and watch for an entry point that fits your plan. Once you are invested, use the Portfolio Command Center to cut through market noise and stay on top of the most important updates that matter for your holdings. For a broader view, tap into the Community to see how other investors are interpreting the same data and key developments. This way you can spot potential catalysts and risks early and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Gilead Sciences

Fresh ideas often move first when momentum builds and potential breakouts start flying before the crowd catches on. Scan hand picked stock lists while it matters and get in early.

• Track income streams that aim to stay steady even when headlines turn noisy by reviewing the curated 8 dividend fortresses designed for investors who care about durable cash returns.
• Spot under the radar growth stories with balance sheets that do not look stretched by scanning the focused 18 high quality undiscovered gems before they stop flying under the radar for now.
• Position ahead of potential infrastructure momentum by checking the curated 36 power grid technology and infrastructure stocks and see which companies could benefit if grid upgrades move from talk to action.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.